NL-OMON21801招募中不适用
Phase 1-2 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer.
VU University Medical Center0 个研究点目标入组 96 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 96
研究概览
简要总结
/A
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Patients with histologically or cytologically confirmed clear-cell mRCC with progressive disease and not amenable to or progressive on or within 6 months of stopping treatment with a VEGF receptor tyrosine kinase inhibitor (sunitinib (or pazopanib) ¡À sorafenib);
- •2. Prior therapy with cytokines (i.e. IL-2, interferon) and/or VEGF-ligand inhibitors (i.e. bevacizumab) is permitted;
排除标准
- •1. Patients currently receiving chemotherapy, immunotherapy, or radiotherapy or who have received these <= 4 weeks prior to visit 1. The wash-out period for sunitinib or sorafenib is at least 2 weeks from the first dose of the study medication;
- •2. Known human immunodeficiency virus (HIV) or other major immunodeficiency;
研究者
相似试验
已完成
2 期
Phase 1-2 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer.Kidney cancer10038364NL-OMON43872Vrije Universiteit Medisch Centrum96
进行中（未招募）
1 期
Phase 1-2 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer.Metastatic renal cell cancerMedDRA version: 12.1Level: LLTClassification code 10050513Term: Metastatic renal cell carcinomaEUCTR2010-024515-13-NLVU University Medical Center
已完成
3 期
Non-inferiority Study of Safety and Efficacy of Everolimus With Low Dose Tacrolimus to Mycophenolate Mofetil With Standard Dose Tacrolimus in Kidney Transplant RecipientsKidney TransplantNCT01025817Novartis Pharmaceuticals613
终止
2 期
Study of Everolimus Treatment in Newly-diagnosed Patients With Advanced Gastrointestinal Neuroendocrine TumorsGastrointestinal TumorsPancreatic TumorsGastrointestinal Neuroendocrine TumorsPancreatic Neuroendocrine TumorsNCT01648465Hellenic Cooperative Oncology Group25
已完成
1 期
Open label Phase I Study of Everolimus(RAD001) plus Doxorubicin in advanced progressive and refractory thyroid cancerC73Malignant neoplasm of thyroid glandDRKS00000635niversitätsklinikum Halle (Saale)14